BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH; ESC Scientific Document Group . 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging 2022:jeac106. [PMID: 36017575 DOI: 10.1093/ehjci/jeac106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Bukhari S, Oliveros E, Parekh H, Farmakis D. Epidemiology, Mechanisms, and Management of Atrial Fibrillation in Cardiac Amyloidosis. Curr Probl Cardiol 2023;48:101571. [PMID: 36584731 DOI: 10.1016/j.cpcardiol.2022.101571] [Reference Citation Analysis]
2 Li L, Jiang X, Xie Q. Prognostic value of left ventricular global longitudinal strain on speckle echocardiography for predicting chemotherapy-induced cardiotoxicity in breast cancer patients: A systematic review and meta-analysis. Echocardiography 2023. [PMID: 36859694 DOI: 10.1111/echo.15548] [Reference Citation Analysis]
3 Floria M, Tănase DM. Myocardial work and permissive cardiotoxicity - A proactive approach in cardio-oncology. J Clin Ultrasound 2023;51:385-7. [PMID: 36893035 DOI: 10.1002/jcu.23385] [Reference Citation Analysis]
4 Mihalcea D, Memis H, Balinisteanu A, Vladareanu AM, Mihaila S, Vinereanu D. Myocardial work-A new tool for early detection of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy induced-cardiotoxicity in hematological patients. J Clin Ultrasound 2023;51:377-84. [PMID: 36331055 DOI: 10.1002/jcu.23388] [Reference Citation Analysis]
5 Teske AJ. Global longitudinal strain in cardio-oncology: worth our trouble or more trouble than it's worth? Neth Heart J 2023;31:101-2. [PMID: 36808401 DOI: 10.1007/s12471-023-01764-5] [Reference Citation Analysis]
6 Mandó P, Waisberg F, Pasquinelli R, Rivero S, Ostinelli A, Perazzo F. HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks. Onco Targets Ther 2023;16:115-32. [PMID: 36844609 DOI: 10.2147/OTT.S335934] [Reference Citation Analysis]
7 Teske AJ. The ESC cardio-oncology 2022 guidelines; the ball is in our court. Eur Heart J Cardiovasc Imaging 2023;24:e45-6. [PMID: 36330679 DOI: 10.1093/ehjci/jeac219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zaborowska-Szmit M, Szmit S, Olszyna-Serementa M, Badurak P, Zajda K, Janowicz-Żebrowska A, Piórek A, Knetki-Wróblewska M, Jaśkiewicz P, Płużański A, Krzakowski M, Kowalski DM. Beta Blockers with Statins May Decrease All-Cause Mortality in Patients with Cardiovascular Diseases and Locally Advanced Unresectable Non-Small-Cell Lung Cancer after Chemoradiotherapy. Cancers (Basel) 2023;15. [PMID: 36831618 DOI: 10.3390/cancers15041277] [Reference Citation Analysis]
9 Foulkes SJ, Howden EJ, Haykowsky MJ, Antill Y, Salim A, Nightingale SS, Loi S, Claus P, Janssens K, Mitchell AM, Wright L, Costello BT, Lindqvist A, Burnham L, Wallace I, Daly RM, Fraser SF, La Gerche A. Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study. Circulation 2023;147:532-45. [PMID: 36342348 DOI: 10.1161/CIRCULATIONAHA.122.062814] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Mathelin C, Cariou E, Vaysse C. [Will the first european cardio-oncology guidelines change the care pathway for women treated for breast cancer?]. Gynecol Obstet Fertil Senol 2023:S2468-7189(23)00034-X. [PMID: 36738861 DOI: 10.1016/j.gofs.2023.02.002] [Reference Citation Analysis]
11 Sparano JA, Sahni G. The ESC Cardio-Oncology Guidelines: A Roadmap for Clinical Practice and Generating Needed Evidence. JACC CardioOncol 2023;5:141-4. [PMID: 36875899 DOI: 10.1016/j.jaccao.2022.10.010] [Reference Citation Analysis]
12 Ritter A, Quartermaine C, Pierre-Charles J, Balasubramanian S, Raeisi-Giglou P, Addison D, Miller E. Cardiotoxicity of Anti-Cancer Radiation Therapy: a Focus on Heart Failure. Curr Heart Fail Rep 2023;20:44-55. [PMID: 36692820 DOI: 10.1007/s11897-023-00587-0] [Reference Citation Analysis]
13 Bart NK. Is the left atrium the key in the amyloid imaging lock? Eur Heart J Cardiovasc Imaging 2023;24:e36. [PMID: 36446467 DOI: 10.1093/ehjci/jeac223] [Reference Citation Analysis]
14 Zhang C, Chen Z, Qin S, Zhu Y, Shu L, Zuo Z. Incidence of adverse cardiovascular events associated with immune checkpoint inhibitors and risk factors for left ventricular dysfunction: A single-center prospective clinical study. Front Cardiovasc Med 2023;10:1052699. [PMID: 36755798 DOI: 10.3389/fcvm.2023.1052699] [Reference Citation Analysis]
15 Ferreira VV, Ghosh AK. Essentials of cardio-oncology. Clin Med (Lond) 2023;23:52-5. [PMID: 36697021 DOI: 10.7861/clinmed.2022-0588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Vallejo-Camazón N, Delgado V. Cardiac Surveillance in Immune Checkpoint Inhibitor Therapy: Biomarkers Versus Imaging. JACC CardioOncol 2022;4:686-8. [PMID: 36636448 DOI: 10.1016/j.jaccao.2022.11.009] [Reference Citation Analysis]
17 Di Nardo P, Lisanti C, Garutti M, Buriolla S, Alberti M, Mazzeo R, Puglisi F. Chemotherapy in patients with early breast cancer: clinical overview and management of long-term side effects. Expert Opinion on Drug Safety 2022. [DOI: 10.1080/14740338.2022.2151584] [Reference Citation Analysis]
18 Giraud EL, van Erp NP, Smolders EJ. QT prolongation with anticancer drugs: a multimodal issue – Authors' reply. The Lancet Oncology 2022;23:e523. [DOI: 10.1016/s1470-2045(22)00695-7] [Reference Citation Analysis]
19 Andres MS, Ramalingam S, Rosen SD, Baksi J, Khattar R, Kirichenko Y, Young K, Yousaf N, Okines A, Huddart R, Harrington K, Furness AJS, Turajlic S, Pickering L, Popat S, Larkin J, Lyon AR. The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment : Including myocarditis and the new entity of non inflammatory left ventricular dysfunction. Cardiooncology 2022;8:21. [PMID: 36424659 DOI: 10.1186/s40959-022-00147-w] [Reference Citation Analysis]
20 Canale ML, Bisceglia I, Gallucci G, Russo G, Camerini A, Di Fusco SA, Paccone A, Camilli M, Fiscella D, Lestuzzi C, Turazza FM, Gulizia MM, Pavan D, Maurea N, Gabrielli D, Oliva F, Colivicchi F. Women at heart: Introducing gender cardio-oncology. Front Cardiovasc Med 2022;9:974123. [PMID: 36505385 DOI: 10.3389/fcvm.2022.974123] [Reference Citation Analysis]
21 Ramos GE, Caglevic C, Bulnes JF, Panay SE, Zapata MI, Daniele AJ, Rodríguez ME. Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.1060813] [Reference Citation Analysis]
22 Cepas-guillén PL, Laffond A, Lozano Granero C, López Lluva MT. III CardioMIR: el Congreso de los Jóvenes Cardiólogos. REC: CardioClinics 2022. [DOI: 10.1016/j.rccl.2022.10.010] [Reference Citation Analysis]
23 Jacquinot Q, Meneveau N, Falcoz A, Bouhaddi M, Roux P, Degano B, Chatot M, Curtit E, Mansi L, Paillard M, Bazan F, Chaigneau L, Dobi E, Meynard G, Vernerey D, Pivot X, Mougin F. Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.1000846] [Reference Citation Analysis]